Skip to main content

Volume 3 Supplement 2

30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015)

  • Poster presentation
  • Open access
  • Published:

Autologous dendritic cell immunotherapy (DCVAC/PCa) added to docetaxel chemotherapy in a Phase III trial (viable) in men with advanced (mCRPC) prostate cancer


Prostate cancer (PCa) is the second most common cancer, and the fifth leading cause of cancer related death among men worldwide. Immunotherapy designed to induce tumor cell specific immune responses capable of destroying tumor cells has emerged as a promising treatment modality in solid malignant tumors. Clinical and preclinical trials have shown that docetaxel chemotherapy can be combined with DCVAC/PCa immunotherapy without impairing the immune response, while Kaplan-Meier analyses showed that patients had a lower risk of death compared with both MSKCC (Hazard Ratio 0.26, 95% CI: 0.13–0.51) and Halabi (Hazard Ratio 0.33, 95% CI: 0.17–0.63) predictions[1].


VIABLE is a randomized, double-blind, placebo-controlled, parallel-group, Phase III study to evaluate, in patients with mCRPC eligible for first-line docetaxel chemotherapy, the efficacy and safety of docetaxel chemotherapy plus DCVAC/PCa (active cellular immunotherapy based on activated dendritic cells) versus docetaxel chemotherapy plus placebo. The study was initiated in May 2014 and plans to enroll almost 1200 patients at approximately 230 sites globally. Eligible patients are required to present with metastatic castrate-resistant PCa defined by both the presence and progression of the disease, maintenance of a castrate state (less than 50 ng/dl), ECOG score 0-2, and adequate hematologic, hepatic and renal functions. All patients will receive standard of care docetaxel plus prednisone, and will be randomized 2:1 to DCVAC/PCa or placebo. Patients will be stratified by region, previous therapy and ECOG status. The primary endpoint is overall survival (OS). Assuming proportional hazards, a two-tailed level of significance of 0.05 and 80% power will be applied. Additionally this design assumes an exponential survival distribution to detect a HR = 0.792 in favor of the DCVAC/PCA group. Registration number NCT02111577, EudraCT number 2012-002814-38.

Trial registration identifier NCT02111577. EudraCT number 2012-002814-38.


  1. Podrazil M, Horvath R, Becht E, et al: Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer. Oncotarget. 2015, May 29 [epub ahead of print]

    Google Scholar 

Download references

Author information

Authors and Affiliations


Rights and permissions

Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.

The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this licence, visit

The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Beer, T.M., Vogelzang, N., Bartůňková, J. et al. Autologous dendritic cell immunotherapy (DCVAC/PCa) added to docetaxel chemotherapy in a Phase III trial (viable) in men with advanced (mCRPC) prostate cancer. j. immunotherapy cancer 3 (Suppl 2), P164 (2015).

Download citation

  • Published:

  • DOI: